Exosome-Based Liquid Biopsy in Biliary Tract Cancer: Nanotechnology-Enabled Strategies and Future Perspectives.
Emerging nanotechnology platforms may enable earlier blood-based detection of biliary tract cancer, a disease caught too late.
This review from Chung-Ang University surveys nanotechnology-enabled exosome isolation and detection platforms for liquid biopsy in biliary tract cancer—a malignancy with extremely high unmet need due to late-stage diagnosis and poor prognosis. It highlights the convergence of advanced nanomaterials (nanoVelcro, SERS, CRISPR-Cas nanosensors), bile-derived exosomes, and AI-based signature interpretation as a pathway toward non-invasive BTC early detection and longitudinal monitoring.
What the study was
- Study design
- comprehensive narrative review with translational technology assessment
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- International Journal of Nanomedicine
Why it surfaced
Timely review of nanotechnology liquid biopsy platforms for biliary tract cancer—a high-unmet-need malignancy where early detection is essentially impossible by standard methods; identified in 48h expanded T3 window (CRDT 2026-08-08).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.